Advertisement

U.S. markets closed

S&P Futures
4,533.50
+9.25(+0.20%)
Dow Futures
34,976.00
+66.00(+0.19%)
Nasdaq Futures
15,078.25
+44.75(+0.30%)
Russell 2000 Futures
2,062.90
+3.70(+0.18%)
Crude Oil
86.55
-0.41(-0.47%)
Gold
1,840.50
-2.70(-0.15%)

Advertisement

CRISPR Therapeutics AG (CRSP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

64.19

-0.86

(-1.32%)

At close: 04:00PM EST

64.25

+0.06

(+0.09%)

After hours:

07:57PM EST

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	65.05
Open	65.91
Bid	64.00 x 1000
Ask	64.25 x 800
Day's Range	63.86 - 68.00
52 Week Range	63.86 - 193.93
Volume	1,842,263
Avg. Volume	1,531,345

Market Cap	4.912B
Beta (5Y Monthly)	2.05
PE Ratio (TTM)	12.20
EPS (TTM)	5.26
Earnings Date	Feb 14, 2022 - Feb 18, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	149.11

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

-10% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for CRSP

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

CRISPR Therapeutics AG
Daily – Vickers Top Buyers & Sellers for 01/18/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Rating
Fair Value
Economic Moat
2 days agoArgus Research

All

News

Press Releases

Research Reports

GuruFocus.com
Aevitas Wealth Management, Inc. Buys Enbridge Inc, Mastercard Inc, Exxon Mobil Corp, Sells ARK ...
Investment company Aevitas Wealth Management, Inc. (Current Portfolio) buys Enbridge Inc, Mastercard Inc, Exxon Mobil Corp, Truist Financial Corp, NVIDIA Corp, sells ARK Innovation ETF, ARK Genomic Revolution ETF, ARK Fintech Innovation ETF, Invesco BulletShares 2021 Corporate Bond ETF, CRISPR Therapeutics AG during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Aevitas Wealth Management, Inc..
Zacks
Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug
Editas' (EDIT) lead pipeline candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. Dependence on partners for collaboration revenues a woe.
- Aab 0119 Btc(edit)
  CoinDesk
- Aab 0119 Chart(edit)
  CoinDesk
Motley Fool
Buy These Stocks If You Want 126% to 206% Returns, Says Wall Street
Shares of clinical-stage biotech companies can skyrocket in a short period based on positive clinical and regulatory news. With that said, let's look at two clinical-stage biotechs that currently boast significant upside potential if we go by average price targets assigned by Wall Street analysts: CRISPR Therapeutics (NASDAQ: CRSP) and Axsome Therapeutics (NASDAQ: AXSM).